SpyGlass Pharma Names Mike Pinder VP of Marketing for BIM-IOL Phase 3 Launch Prep
SGP•SpyGlass Pharma has appointed Mike Pinder as vice president of marketing, leveraging his 20 years of ophthalmology launch experience and award-winning brand campaigns. Pinder will build SpyGlass’s marketing function as the Bimatoprost Drug Pad-IOL System enters two Phase 3 trials and moves toward potential FDA approval and commercialization.
1. Appointment of Mike Pinder
SpyGlass Pharma has named Mike Pinder as vice president of marketing to lead the company’s commercialization efforts. The move underscores the company’s focus on building a robust marketing infrastructure ahead of critical clinical milestones.
2. Driving BIM-IOL Phase 3 and Commercial Strategy
In his new role, Pinder will develop and execute marketing strategies for the Bimatoprost Drug Pad-IOL System as it enrolls participants in two Phase 3 trials. His charge includes preparing for potential FDA approval and the product’s launch into the buy-and-bill specialty pharma market.
3. Extensive Ophthalmology Experience
Pinder brings over 20 years of commercial launch expertise in ophthalmology, including leading brand growth at Astellas Pharma, Novartis and Johnson & Johnson. He is noted for award-winning campaigns and deep experience in buy-and-bill specialty and medical device marketing.
